CDMO Capabilities BSP Pharmaceuticals S.p.A. operates as a contract development and manufacturing organization with end-to-end capabilities from pre-clinical GLP to cGMP manufacturing, including high containment facilities for cytotoxic and high potency oncology drugs, opening doors for outsourcing partnerships across development, scale-up, and commercial supply.

Specialized Platforms The two-segregated facilities support small and large molecules, ADC conjugation and fill finish, peptides, proteins, oligonucleotides, and nano medicines, enabling BSP to target partners pursuing complex biologics and advanced therapies.

Oncology Focus BSP emphasizes cancer therapeutics with capabilities across formulation, process development, optimization, and scalable production, positioning the company to engage with biotech and pharma sponsors advancing cytotoxic, immunotherapy, and high-potency programs.

Strategic Partnerships Past collaborations with CNS Pharmaceuticals and Immunomedics indicate a track record of partnering with oncology-focused innovators, signaling credibility for new clients seeking co-development and manufacturing support on complex oncology assets.

Scale and Financials With a workforce of over one thousand employees and reported revenue between 100 and 250 million, BSP presents as a mid-to-late-stage CDMO with potential for expanded capacity, long-term supply commitments, and multi-project engagements that align with growth-oriented sponsors.